More than half of double vaccinated blood cancer patients have been left with little protection against COVID-19, new research has found. Data from the SOAP-02 trial, published today in a letter to Cancer Cell, examines the level of immune protection following the delayed Pfizer vaccine boost in 159 participants, 128 of whom were cancer patients. Although...